Application of intestinal targeting gastrin-silicon dioxide compound

Abstract

The invention relates to the technical field of medicines, in particular to application of an intestinal targeting gastrin-silicon dioxide compound. Experiments prove that the intestinal targeting gastrin can reduce the abnormal increase of SGLT1 on the BBM caused by high glucose and reduce the absorption of the BBM on glucose in a high-glucose environment, so that the purpose of actively reducing the glucose is achieved; and meanwhile, by increasing secretion of GLP-1 in serum, insulin secretion is promoted, meanwhile, apoptosis of islet b cells is reduced, that is, the functions of islet cells can be recovered to a certain extent while blood sugar is actively reduced, and then the blood sugar reducing effect is achieved.

Description

technical field [0001] The invention relates to the technical field of medicine, in particular to the use of intestinal targeting gastrin-silicon dioxide complex. Background technique [0002] Diabetes mellitus (DM) is a common lifelong metabolic disease caused by the interaction of genetic and environmental factors, and its incidence is rapidly increasing worldwide. According to the International Diabetes Federation (IFD), in 2017 alone, the number of people with diabetes worldwide has reached 451 million, and the number of people with diabetes is expected to increase to 693 million by 2045. Diabetes can be mainly divided into type 1 diabetes, type 2 diabetes, gestational diabetes, etc. Type 1 diabetes (T1DM) is mainly due to the autoimmune system attacking its own islet cells, resulting in lack of insulin secretion, and type 2 diabetes (T2DM) is mainly due to Insulin resistance leads to disturbances in glucose metabolism. Modern medicine believes that diabetes not only m...

AI Technical Summary

Problems solved by technology

(2) Insulin secretion-stimulating drugs mainly act on pancreatic islet b cells, such as sulfonylurea drugs, but such drugs are prone to cause adverse reactions such as hypoglycemia

However, long-term use of such drugs is likely to cause certain damage to the liver

(4) Incretin-like hypoglycemic drugs, such as glucagon-like peptide-1 receptor agonist (GLP-1RA), dipeptidyl peptidase 4 inhibitor (DPP-4 inhibitor), etc., mainly by increasing The level and activity of endogenous GLP-1 promote insulin secretion, which can improve the deteriorating pancreas of patients while controlling blood sugar. Currently, it is only marketed in some countries, and its safety and effectiveness need to be further determined.

[0004] In summary, we found that the existing anti-sugar drugs can not fundamentally solve the situation of patients with elevated blood sugar, but only passively treat the situation when blood sugar is still elevated. hypoglycemic intervention, and the vast majority of antidiabetic drugs mainly act on the pancreas, liver, skeletal muscle, adipose tissue, and kidneys and other organs

The small intestine, as the frontier barrier of blood sugar absorption, is a potential important organ for blood sugar control, but there is still a lack of drug research in this area

Images